Disease · EFO_0009520

contraception

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. contraception. Diseases, record EFO_0009520. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0009520

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: contraception; Open Targets
Open Targets ID: EFO_0009520; Open Targets
Other names: contraceptive management; Open Targets
NCI Thesaurus: C37932; NCI Thesaurus
Highest stage of its drugs: Approval, for 17 of its 31 drugs, from EMA Human Drugs and TTD; Open Targets

Drugs31

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ETHINYL ESTRADIOL	CHEMBL691	Small molecule	Approval	EMA Human Drugs and TTD	26	23	21	Drugs and targets
LEVONORGESTREL	CHEMBL1389	Small molecule	Approval	TTD	20	18	17	Drugs and targets
DROSPIRENONE	CHEMBL1509	Small molecule	Approval	TTD	11	10	10	Drugs and targets
ETONOGESTREL	CHEMBL1531	Small molecule	Approval	TTD	8	7	7	Drugs and targets
COPPER	CHEMBL55643	Small molecule	Approval	TTD	4	3	1	Drugs and targets
DESOGESTREL	CHEMBL1533	Small molecule	Approval	TTD	4	3	3	Drugs and targets
NORELGESTROMIN	CHEMBL1200807	Small molecule	Approval	EMA Human Drugs	4	3	3	Drugs and targets
NORGESTIMATE	CHEMBL1200934	Small molecule	Approval	TTD	4	3	3	Drugs and targets
SEGESTERONE ACETATE	CHEMBL3707377	Small molecule	Approval	TTD	4	3	3	Drugs and targets
DIENOGEST	CHEMBL1201864	Small molecule	Approval	TTD	3	2	2	Drugs and targets

1 to 10 of 31

See all 31 drugs

Targets4

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PGR	Progesterone receptor	18	Progesterone receptor agonist; Progesterone receptor modulator	Approval	https://conductscience.org/library/genes/5241	Drugs and targets
ESR1	Estrogen receptor	7	Estrogen receptor agonist; Estrogen receptor alpha agonist	Approval	https://conductscience.org/library/genes/2099	Drugs and targets
ESR2	Estrogen receptor	2	Estrogen receptor agonist	Phase 3	https://conductscience.org/library/genes/2100	Drugs and targets
NR3C2	Mineralocorticoid receptor	1	Mineralocorticoid receptor antagonist	Approval	https://conductscience.org/library/genes/4306	Drugs and targets

Trials52

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01181479	Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System	Phase 3	1,504	2018-07-03	Contraception	ETHINYL ESTRADIOL, LEVONORGESTREL	Its record names the disease	ClinicalTrials.gov
NCT00185380	Dose-finding Study for the Ultralow-dose Levonorgestrel Intrauterine Contraceptive System (LCS)	Phase 2	742	2010-03-10	Contraception	LEVONORGESTREL	Its record names the disease	ClinicalTrials.gov
NCT00394771	A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale	Phase 2	567	2013-06-19	Breakthrough Bleeding	ETHINYL ESTRADIOL, LEVONORGESTREL	Its record names the disease	ClinicalTrials.gov
NCT02985541	Mirena Extension Trial	Phase 3	364	2022-04-28	Contraception	LEVONORGESTREL	Its record names the disease	ClinicalTrials.gov
NCT00745901	Study to Evaluate Cycle Control With Norgestimate/Ethinyl Estradiol and Drospirenone/Ethinyl Estradiol in Healthy Sexually Active Females	Phase 4	355	2010-05-25	Contraception	DROSPIRENONE, ETHINYL ESTRADIOL, NORGESTIMATE	Its record names the disease	ClinicalTrials.gov
NCT03559010	A Study of Oral Contraception Under Simulated OTC Conditions	Phase 3	189	2022-04-04	Contraception	NORGESTREL	Its record names the disease	ClinicalTrials.gov
NCT02067663	Comparison of the Levonorgestrel IUD and the Copper IUD Placed in the Immediate Postplacental Period: A Prospective Cohort Study		123	2019-07-05	Contraception	LEVONORGESTREL	Its record names the disease	ClinicalTrials.gov
NCT00511355	Effects on Hemostasis, Lipids, Carbohydrate Metabolism, Adrenal & Thyroid Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG-EE (292004)(COMPLETED)(P05764)	Phase 3	121	2011-08-30	Contraception	ESTRADIOL, NOMEGESTROL ACETATE	Its record names the disease	ClinicalTrials.gov
NCT00620464	A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(P05720)	Phase 3	108	2010-05-17	Contraception	ETONOGESTREL	Its record names the disease	ClinicalTrials.gov
NCT00475228	'Levonorgestrel IUD Insertion After D&E Procedure	Phase 4	93	2017-05-09	Contraceptive Usage	LEVONORGESTREL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 52

See all 52 trials

Comparisons in its trials31

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
All AG200-15 vs Lessina: deaths from any cause	0 of 1,273	1 of 344	1,617	NCT01181479	Trial comparisons
All AG200-15 vs Lessina: serious adverse events	14 of 1,273	4 of 344	1,617	NCT01181479	Trial comparisons
NGM/25mcg EE vs DRSP/20mcg EE: serious adverse events	2 of 167	1 of 167	334	NCT00745901	Trial comparisons
NGM/25mcg EE vs DRSP/20mcg EE: Number of Participants With Breakthrough Bleeding/Spotting Cycle 1	53 of 165	56 of 167	332	NCT00745901	Trial comparisons
NGM/25mcg EE vs DRSP/20mcg EE: Number of Participants With Unscheduled Bleeding Cycle 1	72 of 165	74 of 167	332	NCT00745901	Trial comparisons
NGM/25mcg EE vs DRSP/20mcg EE: Number of Participants With Breakthrough Bleeding/Spotting Cycle 2	39 of 160	62 of 165	325	NCT00745901	Trial comparisons
NGM/25mcg EE vs DRSP/20mcg EE: Number of Participants With Unscheduled Bleeding Cycle 2	57 of 160	87 of 165	325	NCT00745901	Trial comparisons
NGM/25mcg EE vs DRSP/20mcg EE: Number of Participants With Unscheduled Bleeding Cycle 3	65 of 157	94 of 159	316	NCT00745901	Trial comparisons
NGM/25mcg EE vs DRSP/20mcg EE: Number of Participants With Breakthrough Bleeding/Spotting Cycle 3	47 of 157	74 of 159	316	NCT00745901	Trial comparisons
Mirena Group vs Paragard Group: serious adverse events	0 of 68	0 of 55	123	NCT02067663	Trial comparisons

1 to 10 of 31

See all 31 comparisons in its trials

Papers from its trials23

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
28188772	RESULT	1	PubMed
24726226	RESULT	1	PubMed
24043457	RESULT	1	PubMed
22222193	RESULT	1	PubMed
22066891	RESULT	1	PubMed
21721590	RESULT	1	PubMed
21679006	RESULT	1	PubMed
21417562	RESULT	1	PubMed
19935020	RESULT	1	PubMed
15937609	RESULT	1	PubMed

1 to 10 of 23

See all 23 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0009520

GET https://conductscience.org/api/diseases/v1/EFO_0009520/drugs?page=2

API reference For AI assistants